Oncology Business Management | Specialty

The Affordable Care Act: An Analysis of Its Impact on Urology Practices

September 20th 2012

For those of us with administrative responsibilities in large urology groups, the dilemma is amplified by the fact that we are affected not only as providers of care but as employers.

The CMS Fee Schedule: Impact on Oncology

September 18th 2012

There are several issues in the Centers for Medicare & Medicaid Services 2012 fee schedule that are of concern to oncologists.

Three Case Studies Highlight the Changing World of Oncology Practice

September 13th 2012

The economics of running an oncology practice is forcing physicians to consider whether they should stay in private practice, join a large network or hospital, or become hospital employees.

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

September 12th 2012

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Dr. Gandara on Patient Selection for Molecular Testing

September 12th 2012

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Enzalutamide Approved for Late-Stage Prostate Cancer

August 31st 2012

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents

August 30th 2012

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

Drug Shortage Dilemma: Trying New Tactics in a Tough Arena

August 29th 2012

Fresh strategies for grappling with the chronic, and at times critical, shortages of cancer drugs that have frustrated the oncology community for the past decade are likely to help alleviate supply problems.

Identification and Prevention of Skeletal-Related Events

August 27th 2012

Immunotherapy for Castration-Resistant Prostate Cancer

August 27th 2012

Optimal Treatment Sequencing for Advanced Prostate Cancer

August 27th 2012

Therapeutic Options for Advanced Prostate Cancer

August 27th 2012

Evidence-Based Care for Localized Prostate Cancer

August 27th 2012

Deciding Treatment Options for Early-Stage Prostate Cancer

August 27th 2012

Robotic-Assisted Laparoscopic Radical Prostatectomies

August 27th 2012

Prostate Cancer Screening and Early Detection, Part III

August 27th 2012

Prostate Cancer Screening and Early Detection, Part I

August 27th 2012

Prostate Cancer Screening and Early Detection, Part II

August 27th 2012

Moore's Law Meets Goldilocks

August 23rd 2012

To be transformative, we need to think outside the box, and maybe it will take a computer visionary and a fairytale to guide us.